Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x doplňuje xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. x., x. 46/2008 Xx. x. x. a x. 47/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 16. listopadu 2011 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno schválení xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx ve xxxxxx.1)
S xxxxx xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Nové xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy dne 1. ledna 2012 x xxxxx dnem xxxxxxxxx v platnost x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Přílohy X x platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx X Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx platné xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 v Paříži xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2012
Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx látky" xxxxx látek xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, M2 x X3.
XXXXX X XXXXXX XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou zakázány.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, zahrnující:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-testosteron (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-5-en-3β,17α-diol | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
androst-5-en-3α,17β-dioI | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-norandrosteron |
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol) | 19-noretiocholanolon |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx xx ně.
Xxx účely xxxxxxx xxxx xxxxx: * "xxxxxxxx" se xxxxxxxx x xxxxx, xxxxxx xxxx není xxxxxxxx xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx přirozeně. |
S2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX LÁTKY
Xxxxxxxxxxx látky x xxxxxx xxxxxxxxxx xxxxxxx xxxx zakázány:
1. Xxxxx xxxxxxxxxxx erytropoesu (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (dEPO), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), methoxypolyethylenglykol-epoetin xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Choriogonadotropin (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx faktor-1 (IGF-1), xxxxxxxxxx růstové faktory (XXX), růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx jiné růstové xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx bílkovin xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových vláken;
x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx (xxxxxx xxxx případných optických xxxxxxx) xxxx zakázáni xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 hodin) x salmeterolu xxxxx xxxx xxxxxx v xxxxxxxx v xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx v moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx xxx 30 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx výše xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, fulvestrant, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. GW 1516) x Agonisté proteinkinasové xxx aktivované AMP x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx účinky. Lokální xxxxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren a xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Soutěži, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení specifické Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx xxxxx x xx, xxxxx xxx byla udělena xx xxxxxxxxxx nebo xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX PŘENOSU XXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx kyslíku, xxxxxxxxxx xxxxxxxxxxxx hemoglobinové xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx ne x xxxxxxxx xxxxx xx xx. Dodávání xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx o xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx kontrole xx zakázané. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale ne x xxxxxxxx pouze xx xx.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx než 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx klinických vyšetřovacích xxxxx.
3. Postupný xxxxx, manipulace x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx xxxx xx xxxxxxxxx systému xx xxxxxxxx.
M3. XXXXXX XXXXXX
X důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx kyselin xxxx jejich xxxxxxxx;
2. Použití normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
LÁTKY X XXXXXX ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx X5 a X1 až M3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx jejich xxxxxxxxxx xxxxxxxxx isomerů) xxxx zakázaná, s xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, fenetylin, xxxxxxxxxxx, fenkamin, fenmetrazin, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx v xxxxx odstavci, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, katin***, efedrin****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, norfenefrin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx jsou xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx je zakázán, xxxxx jeho xxxxxxxxxxx x moči je xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Zakázané xx následujíci:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
S8. KANABINOIDY
Xxxxxxxx (např. xxxxx, xxxxxx a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
LÁTKY XXXXXXXX V URČITÝCH XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude provádět xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx motorismus (UIM)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Při Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (xxxxxxx discipliny) (XXXX)
∙ Xxxxx (XXX)
∙ Xxxx (XXX)
∙ Kuželky x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx a xxxxxxxxxxx lyžování-skoky x X-xxxxx,x snowboard X-xxxxx x "xxx xxx"
∙ Xxxxxxxx x xxxxxxx xxxxxx (CMSB)
∙ Střelba (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (WDF)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:
Acebutolol, xxxxxxxxxx, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 97/2012 Xx. m. x. xxxxx účinnosti xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 98/2013 Sb. m. s. x účinností od 20.12.2013.
Znění xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, pokud xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.